查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1642673

2025-2033 年按給藥途徑、適應症、配銷通路和地區分類的特種學名藥市場報告

Specialty Generics Market Report by Route of Administration, Indication, Distribution channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 127 Pages | 商品交期: 2-3個工作天內

價格

2024年全球特種學名藥IMARC Group規模達818億美元。推動市場發展的因素有很多，包括旨在利用能力、資源和市場影響力的策略合作數量不斷增加、線上藥局和遠距醫療平台的發展以及有利的政府措施。

特種學名藥是指高成本品牌特用藥物的學名藥。這些藥物用於治療複雜的慢性疾病，例如癌症、類風濕性關節炎、多發性硬化症和愛滋病毒。它們與傳統學名藥的不同之處在於，它們通常是基於生物製劑的，需要特殊處理和給藥（通常是注射劑），並且通常透過有限的網路進行分發。由於所涉及分子的複雜性質以及製造過程中使用的複雜工藝，特種學名藥的開發面臨獨特的挑戰。因此，與傳統學名藥相比，其核准監管途徑可能更加嚴格。此外，特種學名藥在醫療保健領域具有巨大的潛力。它們以較低的成本為患者提供重要的治療，同時也減輕了醫療保健系統的財務負擔。

線上藥局和遠距醫療平台等先進分銷管道的發展也推動了特種學名藥市場的成長。這些管道有助於輕鬆取得藥物，確保即使是偏遠地區的患者也能獲得所需的藥物。與此同時，政府醫療保健計劃和私人付款人正在不斷尋求控制不斷上漲的醫療保健成本的策略。強調使用學名藥，特別是特種學名藥，是一個主要策略。因此，一些政府和保險公司現在鼓勵或強制規定學名藥的處方，從而推動需求。此外，價格較實惠的特種學名藥已成為該地區許多人的首選，確保更多人口能夠獲得基本治療。因此，這極大地支撐了市場。除此之外，針對更多利基和特殊條件的學名藥的生產正在為市場做出貢獻。此外，旨在利用合作實體的能力、資源和市場影響力的策略合作正在創造積極的市場前景。

特殊學名藥市場趨勢/促進因素：

對經濟實惠的醫療保健解決方案的需求不斷成長

隨著全球人口持續成長和非傳染性疾病 (NCD) 負擔的擴大，人們大力推動提供負擔得起的醫療保健解決方案。特種學名藥產業具有獨特的優勢來滿足這一需求。特種學名藥是品牌藥物的生物等效版本，為患者和醫療保健系統提供創新藥物的治療功效，但成本較低。此外，日本、美國和許多歐洲國家等已開發國家的人口老化導致慢性病發生率增加。這些疾病通常需要長期且複雜的治療方案，這可能會對個人和國家醫療保健系統造成經濟負擔。此外，在發展中國家，中產階級人口的擴張及其對先進醫療保健解決方案的需求給現有基礎設施帶來了壓力。

品牌藥的專利到期

特種學名藥產業最重要的促進因素之一是品牌藥物專利的到期。當專利到期時，它為其他製造商生產和銷售這些藥物的學名藥打開了大門。鑑於學名藥的研發 (R&D) 成本通常低於新藥，因此這些藥物的定價更便宜，同時保持療效。每年都有年銷售額數十億美元的藥品失去專利保護。這為特種學名藥製造商提供了一個千載難逢的機會，可以進入擁有現成消費者基礎的成熟市場。因此，這些藥物的可及性將使更廣泛的人群受益，特別是中低收入家庭的人群，從而對市場產生積極影響。

藥物開發的技術進步

特種學名藥行業正在隨著更廣泛的製藥行業的發展而發展。同時，藥物開發和製造的最新技術進步使得更複雜的學名藥的生產成為可能，例如生物學名藥，而這在以前很難生產。此外，人工智慧和先進分析方法等工具簡化了這些藥物的研發 (R&D) 流程。這意味著專業學名藥製造商現在可以解決比以往更廣泛的疾病和疾病。此外，製造流程的創新確保這些藥物的生產品質穩定，並符合全球監管機構制定的嚴格標準。因此，它也為市場做出了貢獻。

特殊學名藥市場細分：

依給藥途徑分類：

注射劑

口服

其他

注射劑佔市場主導地位

注射給藥途徑已成為特種學名藥產業的重要市場驅動力。這種成長可歸因於慢性病和複雜醫療狀況的日益普及。注射劑具有多種優點，包括精確劑量和快速起效，使其適合管理危急的健康狀況。此外，某些品牌生物製劑和特種藥物的專利到期為學名藥製造商提供具有成本效益的替代品進入市場打開了大門。此外，製藥業對研發的日益關注導致了治療效果改善的創新注射產品。這些市場促進因素共同促進了注射劑給藥途徑在特種學名藥行業的成長和突出。

相反，由於消費者偏好的變化，口服給藥途徑作為特種學名藥行業的市場促進因素發揮關鍵作用。許多患者喜歡口服製劑，因為易於給藥，無需注射並減少潛在的不適。除此之外，大量需要長期治療的慢性疾病和病症也促進了口服藥物的普及。

按指示細分：

腫瘤學

自體免疫疾病

傳染病

其他

腫瘤學佔市場主導地位

全球癌症盛行率持續上升，因此需要持續需求有效且負擔得起的腫瘤治療。隨著越來越多的患者需要長期治療，特種學名藥的可及性和成本效益對於改善癌症護理變得至關重要。此外，一些品牌腫瘤藥物的專利到期為學名藥製造商進入市場提供了機會，在不影響品質的情況下提供更實惠的替代品。除此之外，研究和技術的進步促進了創新製劑和藥物輸送系統的開發，提高了腫瘤學學名藥的療效和患者依從性。此外，旨在透過促進學名藥使用來減輕癌症負擔的政府措施和政策進一步推動了市場成長。

另一方面，受包括疫情和大流行在內的全球傳染病負擔的影響，傳染病給藥途徑已成為特種學名藥行業的關鍵市場促進因素，這凸顯了對有效且可及的治療方案的迫切需要。

按配銷通路分類：

零售藥局

專業藥房

醫院藥房

零售藥局主導市場

零售藥局配銷通路作為特種學名藥行業的市場驅動力發揮關鍵作用，主要受到零售藥局廣泛存在的影響，確保向更廣泛的患者群體方便、可及地分銷特種學名藥。由於這些藥房通常位於各個社區和街區，患者可以輕鬆獲得處方藥物，而不需要專門的醫療設施。此外，慢性病盛行率的上升以及對長期治療選擇的需求不斷成長，放大了零售藥局在提供特殊學名藥方面的重要性。此外，零售藥局與醫療保健提供者建立的關係可以簡化溝通和協作，促進高效的處方處理和病患照護。隨著對特種學名藥的需求持續成長，零售藥局在分銷和患者支援方面的重要作用將加強該行業的擴張和關鍵藥物的可及性。

按地區分類：

北美洲

美國

加拿大

歐洲

義大利

德國

西班牙

英國

法國

亞太

中國

印度

日本

韓國

拉丁美洲

巴西

墨西哥

中東和非洲

北美表現出明顯的主導地位，佔據最大的特種學名藥市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；歐洲（義大利、德國、法國、英國和西班牙）；亞太地區（日本、中國、印度和韓國）；拉丁美洲（巴西、墨西哥）；以及中東和非洲。報告稱，北美佔據最大的市場佔有率。

北美地區的發展受到慢性病和複雜醫療狀況日益普及的推動。這導致對專業治療方案的需求不斷成長。特種學名藥以其具有成本效益的品牌特種藥替代品，在有效管理這些疾病方面獲得了關注。此外，某些品牌專科藥物的專利到期為學名藥製造商進入市場創造了機會，為患者提供更實惠的治療選擇。此外，旨在促進學名藥使用的有利政府政策和措施也支持了北美特種學名藥產業的擴張。這些政策鼓勵學名藥的使用，從而增加患者的可及性並節省醫療保健系統的整體成本。此外，研究和開發的進步導致推出具有改善治療效果的創新專業學名藥，正在對市場產生積極影響。

競爭格局：

由於開發創新配方、藥物輸送系統和聯合療法以提高產品功效和患者依從性的研發投資不斷增加，全球特種學名藥市場正在經歷顯著成長。確保遵守監管標準並獲得各國衛生當局的必要批准是專業學名藥公司推出和行銷其產品的關鍵方面。同時，產品組合的擴展涵蓋更廣泛的治療領域，例如腫瘤學、免疫學和罕見疾病，以滿足不同患者的需求，正在對市場產生積極影響。除此之外，公司還提供患者支持計劃，為患者提供諮詢、依從性援助和經濟援助，從而改善患者的治療效果和藥物依從性。此外，與製藥公司、研究機構和醫療保健組織的合作使特種學名藥公司能夠獲得新技術，從而為市場做出貢獻。

該報告對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。市場上的一些主要參與者包括：

梯瓦製藥工業公司

阿康公司

邁蘭公司

馬林克羅特

山德士國際有限公司

輝瑞公司

太陽製藥工業有限公司

威朗製藥公司

阿波泰克斯公司

遠藤國際有限公司

本報告回答的關鍵問題

  • 全球特種學名藥市場規模有多大
  • 推動全球特種學名藥市場的關鍵因素是什麼
  • COVID-19 對全球特種學名藥市場有何影響
  • 基於給藥途徑的全球特種學名藥市場的分類是怎樣的
  • 根據適應症，全球特種學名藥市場的詳細情形如何
  • 基於配銷通路的全球特種學名藥市場的細分是什麼
  • 全球特種學名藥市場的關鍵區域有哪些
  • 誰是全球特種學名藥市場的主要參與者/公司

本報告回答的關鍵問題

  • 全球特種學名藥市場規模有多大？推動全球特種學名藥市場的關鍵因素是什麼？
  • COVID-19 對全球特種學名藥市場有何影響？
  • 根據給藥途徑，全球特種學名藥市場的詳細情形如何？
  • 根據此適應症，全球特種學名藥市場的詳細情形如何？
  • 基於配銷通路的全球特種學名藥市場的詳細情形如何？
  • 全球特種學名藥市場的關鍵區域有哪些？
  • 全球特種學名藥市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：全球特種學名藥市場：簡介

第 5 章：為什麼特種學名藥如此有利可圖？

第 6 章：全球特種學名藥市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場區隔：依給藥途徑
  • 市場區隔：依指標
  • 市場區隔：按配銷通路
  • 市場區隔：按地區
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅
  • 主要市場促進因素與成功因素

第 7 章：市場區隔：依管理途徑

  • 可注射
    • 市場趨勢
    • 市場預測
  • 口服
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依跡象

  • 腫瘤學
    • 市場趨勢
    • 市場預測
  • 自體免疫疾病
    • 市場趨勢
    • 市場預測
  • 傳染病
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按配銷通路

  • 零售藥局
    • 市場趨勢
    • 市場預測
  • 專業藥房
    • 市場趨勢
    • 市場預測
  • 醫院藥房
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 市場概況
    • 市場表現
    • 市場細分：按國家/地區
    • 市場預測
  • 歐洲
    • 市場概況
    • 市場表現
    • 市場細分：按國家/地區
    • 市場預測
  • 亞太地區
    • 市場概況
    • 市場表現
    • 市場細分：按國家/地區
    • 市場預測
  • 拉丁美洲
    • 市場概況
    • 市場表現
    • 市場細分：按國家/地區
    • 市場預測
  • 中東和非洲
    • 市場概況
    • 市場表現
    • 市場預測

第 11 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Teva Pharmaceuticals Industries
    • Akorn, Inc.
    • Mylan NV
    • Mallinckrodt
    • Sandoz International GmbH
    • Pfizer, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Valeant Pharmaceuticals
    • Apotex Corp.
    • Endo International plc.
Product Code: SR112024A1219

The global specialty generics market size reached USD 81.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 178.6 Billion by 2033, exhibiting a growth rate (CAGR) of 9.1% during 2025-2033. There are various factors that are driving the market, which include rising number of strategic collaborations aiming to leverage the capabilities, resources, and market presence, the evolution of online pharmacies and telemedicine platforms, and favorable government initiatives.

Specialty generics refer to generic versions of high-cost, brand-name specialty drugs. These medications are used to treat complex, chronic conditions such as cancer, rheumatoid arthritis, multiple sclerosis, and HIV. They differ from traditional generics in that they are typically biologic-based, require special handling and administration often injectables, and are often distributed through limited networks. The development of specialty generics presents unique challenges due to the intricate nature of the molecules involved and the complex processes used in their manufacturing. As a result, regulatory pathways for their approval can be more stringent compared to conventional generic drugs. In addition, specialty generics hold immense potential in healthcare. They offer patients access to vital treatments at a reduced cost, while also alleviating the financial burden on healthcare systems.

The evolution of advanced distribution channels, such as online pharmacies and telemedicine platforms, has also propelled the growth of the specialty generics market. These channels facilitate easy access to medications, ensuring patients in even remote locations can obtain the drugs they need. Along with this, government healthcare programs and private payers are continuously seeking strategies to contain escalating healthcare costs. Emphasizing the use of generic drugs, especially specialty generics, is a primary strategy. Therefore, several governments and insurance companies now incentivize or mandate the prescription of generics where available, thereby driving demand. In addition, specialty generics, being more affordably priced, have become the preferred choice for many in regions, ensuring essential treatments are within reach of larger segments of the population. Thus, this is significantly supporting the market. Apart from this, the production of generics for more niche, and specialized conditions is contributing to the market. Moreover, strategic collaborations aiming to leverage the capabilities, resources, and market presence of partnering entities are creating a positive market outlook.

Specialty Generics Market Trends/Drivers:

Increasing Demand for Affordable Healthcare Solutions

As the global population continues to rise and the burden of non-communicable diseases (NCDs) expands, there's a significant push to provide affordable healthcare solutions. The specialty generics industry is uniquely poised to address this demand. Specialty generics, which are bioequivalent versions of brand-name drugs, offer patients and healthcare systems the therapeutic efficacy of innovative medicines but at a reduced cost. Additionally, aging populations in various developed countries, such as Japan, the United States, and numerous European nations, are leading to an increased incidence of chronic diseases. These conditions often require prolonged and complex treatment regimens, which can be financially taxing for both individuals and national healthcare systems. Furthermore, in developing nations, the expansion of middle-class populations and their demand for advanced healthcare solutions is putting a strain on existing infrastructures.

Patent Expirations of Branded Drugs

One of the most significant drivers of the specialty generics industry is the expiration of patents for branded drugs. When patents expire, it opens the door for other manufacturers to produce and market generic versions of those medications. Given that research and development (R&D) costs for generics are typically lower than for novel drugs, these medications can be priced more affordably while maintaining therapeutic efficacy. Each year, drugs with billions of dollars in annual sales lose patent protection. This presents a golden opportunity for specialty generic manufacturers to tap into established markets with a ready consumer base. Thus, the accessibility of these medications then benefits the wider population, especially those in low-to-middle-income households, positively influencing the market.

Technological Advancements in Drug Development

The specialty generics industry is evolving with the broader pharmaceutical sector. Along with this, recent technological advancements in drug development and manufacturing are enabling the production of more complex generics, such as biosimilars, which were previously challenging to produce. In addition, tools, such as artificial intelligence and advanced analytical methodologies have streamlined the research and development (R&D) process for these drugs. This means that specialty generic manufacturers now address a broader range of diseases and conditions than ever before. Furthermore, innovations in manufacturing processes are ensuring that these drugs are produced with consistent quality, meeting the rigorous standards set by global regulatory bodies. As a result, it is also contributing to the market.

Specialty Generics Market Segmentation:

Breakup by Route of Administration:

Injectables

Oral

Others

Injectable dominates the market

The injectables route of administration has emerged as a significant market driver within the specialty generics industry. This growth can be attributed to the increasing prevalence of chronic diseases and complex medical conditions. Injectables offer advantages, including precise dosing and rapid onset of action, making them suitable for managing critical health conditions. In addition, the expiration of patents for certain branded biologics and specialty drugs has opened doors for generic manufacturers to enter the market with cost-effective alternatives. Moreover, the rising focus on research and development in the pharmaceutical sector has led to innovative injectable products with improved therapeutic outcomes. These market drivers collectively contribute to the growth and prominence of the injectables route of administration in the specialty generics industry.

On the contrary, the oral route of administration plays a pivotal role as a market driver within the specialty generics industry, due to the changing consumer preferences. Numerous patients prefer oral formulations due to ease of administration, eliminating the need for injections and reducing potential discomfort. Along with this, the vast array of chronic diseases and conditions requiring long-term treatment has contributed to the popularity of oral drugs.

Breakup by Indication:

Oncology

Autoimmune Diseases

Infectious Diseases

Others

Oncology dominates the market

The rising prevalence of cancer continues to rise globally, necessitating a constant demand for effective and affordable oncology treatments. With an increasing number of patients requiring long-term therapies, the accessibility and cost-effectiveness of specialty generics become essential in improving cancer care. In addition, the expiration of patents for several branded oncology drugs has opened opportunities for generic manufacturers to enter the market, offering more affordable alternatives without compromising on quality. Apart from this, advancements in research and technology have led to the development of innovative formulations and drug delivery systems, enhancing the efficacy and patient compliance of oncology generics. Moreover, government initiatives and policies aimed at reducing the burden of cancer by promoting generic drug usage have further propelled market growth.

On the other hand, the infectious diseases route of administration has emerged as a crucial market driver within the specialty generics industry, influenced by the ongoing global burden of infectious diseases, including outbreaks and pandemics, has underscored the urgent need for effective and accessible treatment options.

Breakup by Distribution channel:

Retail Pharmacies

Specialty Pharmacies

Hospital Pharmacies

Retail pharmacies dominates the market

The retail pharmacies distribution channel plays a pivotal role as a market driver within the specialty generics industry, primarily influenced by the widespread presence of retail pharmacies ensuring convenient and accessible distribution of specialty generic medications to a broader patient base. As these pharmacies are typically located in various communities and neighborhoods, patients can easily access their prescribed medications without the need for specialized healthcare facilities. In addition, the rising prevalence of chronic diseases and the growing demand for long-term treatment options have amplified the significance of retail pharmacies in delivering specialty generics. Furthermore, the retail pharmacies' established relationships with healthcare providers allow for streamlined communication and collaboration, facilitating efficient prescription processing and patient care. As the demand for specialty generics continues to grow, retail pharmacies' essential role in distribution and patient support is set to reinforce the industry's expansion and accessibility to critical medications.

Breakup by Region:

North America

United States

Canada

Europe

Italy

Germany

Spain

United Kingdom

France

Asia-Pacific

China

India

Japan

South Korea

Latin America

Brazil

Mexico

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest specialty generics market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Europe (Italy, Germany, France, United Kingdom, and Spain); Asia Pacific (Japan, China, India, and South Korea); Latin America (Brazil, Mexico); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The North America region is driven by the increasing prevalence of chronic diseases and complex medical conditions. It is leading to a growing demand for specialized treatment options. Specialty generics, with their cost-effective alternatives to branded specialty drugs, have gained traction in managing these conditions effectively. Additionally, the expiration of patents for certain branded specialty medications has created opportunities for generic manufacturers to enter the market, providing patients with more affordable treatment options. In addition, favorable government policies and initiatives aimed at promoting the use of generic medications have supported the expansion of the specialty generics industry in North America. These policies encourage generic drug usage, leading to enhanced patient access and overall cost savings in the healthcare system. Moreover, advancements in research and development leading to the introduction of innovative specialty generics with improved therapeutic outcomes are positively influencing the market.

Competitive Landscape:

The global specialty generics market is experiencing significant growth due to the escalating investments in research and development to develop innovative formulations, drug delivery systems, and combination therapies to improve the efficacy and patient compliance of their products. Ensuring compliance with regulatory standards and obtaining necessary approvals from health authorities in various countries is a critical aspect for specialty generic companies to launch and market their products. Along with this, the expansion of product portfolios to cover a wider range of therapeutic areas, such as oncology, immunology, and rare diseases, to cater to diverse patient needs is positively influencing the market. Apart from this, companies are offering patient support programs that provide counseling, adherence assistance, and financial aid to patients, thereby improving patient outcomes and medication adherence. Furthermore, collaborating with pharmaceutical companies, research institutions, and healthcare organizations allows specialty generics companies to access new technologies is contributing to the market.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Teva Pharmaceuticals Industries

Akorn, Inc.

Mylan N.V.

Mallinckrodt

Sandoz International GmbH

Pfizer, Inc.

Sun Pharmaceutical Industries Ltd.

Valeant Pharmaceuticals

Apotex Corp.

Endo International plc

Key Questions Answered in This Report

  • 1. What is the size of the global specialty generics market?
  • 2. What are the key factors driving the global specialty generics market?
  • 3. What has been the impact of COVID-19 on the global specialty generics market?
  • 4. What is the breakup of the global specialty generics market based on the route of administration?
  • 5. What is the breakup of the global specialty generics market based on the indication?
  • 6. What is the breakup of the global specialty generics market based on the distribution channel?
  • 7. What are the key regions in the global specialty generics market?
  • 8. Who are the key players/companies in the global specialty generics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Global Specialty Generics Market: Introduction

5 Why are Specialty Generics So Lucrative?

6 Global Specialty Generics Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Breakup by Route of Administration
  • 6.5 Market Breakup by Indication
  • 6.6 Market Breakup by Distribution Channel
  • 6.7 Market Breakup by Region
  • 6.8 Market Forecast
  • 6.9 SWOT Analysis
    • 6.9.1 Overview
    • 6.9.2 Strengths
    • 6.9.3 Weaknesses
    • 6.9.4 Opportunities
    • 6.9.5 Threats
  • 6.10 Value Chain Analysis
  • 6.11 Porters Five Forces Analysis
    • 6.11.1 Overview
    • 6.11.2 Bargaining Power of Buyers
    • 6.11.3 Bargaining Power of Suppliers
    • 6.11.4 Degree of Competition
    • 6.11.5 Threat of New Entrants
    • 6.11.6 Threat of Substitutes
  • 6.12 Key Market Drivers and Success Factors

7 Market Breakup by Route of Administration

  • 7.1 Injectable
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Oral
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Autoimmune Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infectious Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Retail Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Specialty Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Hospital Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 Market Overview
    • 10.1.2 Market Performance
    • 10.1.3 Market Breakup by Country
      • 10.1.3.1 United States
        • 10.1.3.1.1 Market Trends
        • 10.1.3.1.2 Market Forecast
      • 10.1.3.2 Canada
        • 10.1.3.2.1 Market Trends
        • 10.1.3.2.2 Market Forecast
    • 10.1.4 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Overview
    • 10.2.2 Market Performance
    • 10.2.3 Market Breakup by Country
      • 10.2.3.1 Italy
        • 10.2.3.1.1 Market Trends
        • 10.2.3.1.2 Market Forecast
      • 10.2.3.2 Germany
        • 10.2.3.2.1 Market Trends
        • 10.2.3.2.2 Market Forecast
      • 10.2.3.3 France
        • 10.2.3.3.1 Market Trends
        • 10.2.3.3.2 Market Forecast
      • 10.2.3.4 United Kingdom
        • 10.2.3.4.1 Market Trends
        • 10.2.3.4.2 Market Forecast
      • 10.2.3.5 Spain
        • 10.2.3.5.1 Market Trends
        • 10.2.3.5.2 Market Forecast
    • 10.2.4 Market Forecast
  • 10.3 Asia Pacific
    • 10.3.1 Market Overview
    • 10.3.2 Market Performance
    • 10.3.3 Market Breakup by Country
      • 10.3.3.1 Japan
        • 10.3.3.1.1 Market Trends
        • 10.3.3.1.2 Market Forecast
      • 10.3.3.2 China
        • 10.3.3.2.1 Market Trends
        • 10.3.3.2.2 Market Forecast
      • 10.3.3.3 India
        • 10.3.3.3.1 Market Trends
        • 10.3.3.3.2 Market Forecast
      • 10.3.3.4 South Korea
        • 10.3.3.4.1 Market Trends
        • 10.3.3.4.2 Market Forecast
    • 10.3.4 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Market Overview
    • 10.4.2 Market Performance
    • 10.4.3 Market Breakup by Country
      • 10.4.3.1 Brazil
        • 10.4.3.1.1 Market Trends
        • 10.4.3.1.2 Market Forecast
      • 10.4.3.2 Mexico
        • 10.4.3.2.1 Market Trends
        • 10.4.3.2.2 Market Forecast
    • 10.4.4 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Overview
    • 10.5.2 Market Performance
    • 10.5.3 Market Forecast

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 Teva Pharmaceuticals Industries
    • 11.3.2 Akorn, Inc.
    • 11.3.3 Mylan N.V.
    • 11.3.4 Mallinckrodt
    • 11.3.5 Sandoz International GmbH
    • 11.3.6 Pfizer, Inc.
    • 11.3.7 Sun Pharmaceutical Industries Ltd.
    • 11.3.8 Valeant Pharmaceuticals
    • 11.3.9 Apotex Corp.
    • 11.3.10 Endo International plc.

List of Figures

  • Figure 1: Global: Specialty Generics Market: Major Drivers and Challenges
  • Figure 2: Global: Specialty Generics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Specialty Generics Market: Breakup by Route of Administration (in %), 2024
  • Figure 4: Global: Specialty Generics Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Specialty Generics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 6: Global: Specialty Generics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Specialty Generics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Specialty Generics Industry: SWOT Analysis
  • Figure 9: Global: Specialty Generics Industry: Value Chain Analysis
  • Figure 10: Global: Specialty Generics Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Specialty Generics Market (Administration through Injectables): Sales Value (in Billion USD), 2019 & 2024
  • Figure 12: Global: Specialty Generics Market (Administration through Injectables) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 13: Global: Specialty Generics Market (Oral Administration): Sales Value (in Billion USD), 2019 & 2024
  • Figure 14: Global: Specialty Generics Market (Oral Administration) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 15: Global: Specialty Generics Market (Other Routes of Administration): Sales Value (in Billion USD), 2019 & 2024
  • Figure 16: Global: Specialty Generics Market (Other Routes of Administration) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 17: Global: Specialty Generics Market (Oncology): Sales Value (in Billion USD), 2019 & 2024
  • Figure 18: Global: Specialty Generics Market (Oncology) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 19: Global: Specialty Generics Market (Autoimmune Diseases): Sales Value (in Billion USD), 2019 & 2024
  • Figure 20: Global: Specialty Generics Market (Autoimmune Diseases) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 21: Global: Specialty Generics Market (Infectious Diseases): Sales Value (in Billion USD), 2019 & 2024
  • Figure 22: Global: Specialty Generics Market (Infectious Diseases) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 23: Global: Specialty Generics Market (Other Indications): Sales Value (in Billion USD), 2019 & 2024
  • Figure 24: Global: Specialty Generics Market (Other Indications) Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 25: Global: Specialty Generics Market: Sales Through Retail Pharmacies (in Billion USD), 2019 & 2024
  • Figure 26: Global: Specialty Generics Market Forecast: Sales Through Retail Pharmacies (in Billion USD), 2025-2033
  • Figure 27: Global: Specialty Generics Market: Sales Through Specialty Pharmacies (in Billion USD), 2019 & 2024
  • Figure 28: Global: Specialty Generics Market Forecast: Sales Through Specialty Pharmacies (in Billion USD), 2025-2033
  • Figure 29: Global: Specialty Generics Market: Sales Through Hospital Pharmacies (in Billion USD), 2019 & 2024
  • Figure 30: Global: Specialty Generics Market Forecast: Sales Through Hospital Pharmacies (in Billion USD), 2025-2033
  • Figure 31: North America: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: North America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: United States: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: United States: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Canada: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Canada: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Europe: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Europe: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Italy: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Italy: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Germany: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Germany: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: France: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: France: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United Kingdom: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United Kingdom: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Spain: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Spain: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Asia Pacific: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Asia Pacific: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: India: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: India: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: South Korea: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: South Korea: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Latin America: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Latin America: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Brazil: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Brazil: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Mexico: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Mexico: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Middle East and Africa: Specialty Generics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Middle East and Africa: Specialty Generics Market: Breakup by Country (in %), 2024
  • Figure 67: Middle East and Africa: Specialty Generics Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Specialty Generics Market Forecast: Breakup by Route of Administration (in Billion USD), 2025-2033
  • Table 3: Global: Specialty Generics Market Forecast: Breakup by Indication (in Billion USD), 2025-2033
  • Table 4: Global: Specialty Generics Market Forecast: Breakup by Distribution Channel (in Billion USD), 2025-2033
  • Table 5: Global: Specialty Generics Market Forecast: Breakup by Region (in Billion USD), 2025-2033
  • Table 6: North America: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 7: Europe: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 8: Asia Pacific: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 9: Latin America: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 10: Middle East and Africa: Specialty Generics Market: Key Industry Highlights, 2024 and 2033
  • Table 11: Global: Specialty Generics Market Structure
  • Table 12: Global: Specialty Generics Market: Key Players